This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nyberg, P. Articles by Kalluri, R. Search for Related Content PubMed PubMed Citation Articles by Nyberg, P. Articles by Kalluri, R. Related Collections Tumor Biology Tumor Biology: Angiogenesis

Endogenous Inhibitors of Angiogenesis

Center for Matrix Biology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts

Requests for reprints: Raghu Kalluri, Center for Matrix Biology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Avenue, Dana 514, Boston, MA 02215. Phone: 617-667-0445; Fax: 617-975-5663; E-mail: rkalluri{at}bidmc.harvard.edu.

Angiogenesis, the formation of new blood vessels, is required for many pathologic processes, including invasive tumor growth as well as physiologic organ/tissue maintenance. Angiogenesis during development and adulthood is likely regulated by a balance between endogenous proangiogenic and antiangiogenic factors. It is speculated that tumor growth requires disruption of such balance; thus, the angiogenic switch must be turned "on" for cancer progression. If the angiogenic switch needs to be turned on to facilitate the tumor growth, the question remains as to what the physiologic status of this switch is in the adult human body; is it "off," with inhibitors outweighing the stimulators, or maintained at a fine "balance," keeping the proangiogenic properties of many factors at a delicate "activity" balance with endogenous inhibitors of angiogenesis. The physiologic status of this balance is important to understand as it might determine an individual's predisposition to turn the switch on during pathologic events dependent on angiogenesis. Conceivably, if the physiologic angiogenesis balance in human population exists somewhere between off and even balance, an individual's capacity and rate to turn the switch on might reflect their normal physiologic angiogenic status. In this regard, although extensive knowledge has been gained in our understanding of endogenous growth factors that stimulate angiogenesis, the activities associated with endogenous inhibitors are poorly understood. In this review, we will present an overview of the knowledge gained in studies related to the identification and characterization of 27 different endogenous inhibitors of angiogenesis.

This article has been cited by other articles:

				B. Ng, J. Zakrzewski, M. Warycha, P. J. Christos, D. F. Bajorin, R. L. Shapiro, R. S. Berman, A. C. Pavlick, D. Polsky, M. Mazumdar, et al. Shedding of Distinct Cryptic Collagen Epitope (HU177) in Sera of Melanoma Patients Clin. Cancer Res., October 1, 2008; 14(19): 6253 - 6258. [Abstract] [Full Text] [PDF]

				E. D. Karagiannis and A. S. Popel A systematic methodology for proteome-wide identification of peptides inhibiting the proliferation and migration of endothelial cells PNAS, September 16, 2008; 105(37): 13775 - 13780. [Abstract] [Full Text] [PDF]

				J. K. Willmann, A. M. Lutz, R. Paulmurugan, M. R. Patel, P. Chu, J. Rosenberg, and S. S. Gambhir Dual-targeted Contrast Agent for US Assessment of Tumor Angiogenesis in Vivo Radiology, September 1, 2008; 248(3): 936 - 944. [Abstract] [Full Text] [PDF]

				C. Rampon, S. Bouillot, A. Climescu-Haulica, M.-H. Prandini, F. Cand, Y. Vandenbrouck, and P. Huber Protocadherin 12 deficiency alters morphogenesis and transcriptional profile of the placenta Physiol Genomics, July 9, 2008; 34(2): 193 - 204. [Abstract] [Full Text] [PDF]

				W. Cai and X. Chen Multimodality Molecular Imaging of Tumor Angiogenesis J. Nucl. Med., June 1, 2008; 49(Suppl_2): 113S - 128S. [Abstract] [Full Text] [PDF]

				R. S. Kerbel Tumor Angiogenesis N. Engl. J. Med., May 8, 2008; 358(19): 2039 - 2049. [Full Text] [PDF]

				L. Jakobsson, A. Domogatskaya, K. Tryggvason, D. Edgar, and L. Claesson-Welsh Laminin deposition is dispensable for vasculogenesis but regulates blood vessel diameter independent of flow FASEB J, May 1, 2008; 22(5): 1530 - 1539. [Abstract] [Full Text] [PDF]

				T. Levchenko, N. Veitonmaki, A. Lundkvist, H. Gerhardt, Y. Ming, K. Berggren, A. Kvanta, R. Carlsson, and L. Holmgren Therapeutic antibodies targeting angiomotin inhibit angiogenesis in vivo FASEB J, March 1, 2008; 22(3): 880 - 889. [Abstract] [Full Text] [PDF]

				N. T. Fernando, M. Koch, C. Rothrock, L. K. Gollogly, P. A. D'Amore, S. Ryeom, and S. S. Yoon Tumor Escape from Endogenous, Extracellular Matrix-Associated Angiogenesis Inhibitors by Up-Regulation of Multiple Proangiogenic Factors Clin. Cancer Res., March 1, 2008; 14(5): 1529 - 1539. [Abstract] [Full Text] [PDF]

				L. Xie, K. Palmsten, B. MacDonald, M. W. Kieran, S. Potenta, S. Vong, and R. Kalluri Basement Membrane Derived Fibulin-1 and Fibulin-5 Function as Angiogenesis Inhibitors and Suppress Tumor Growth Experimental Biology and Medicine, February 1, 2008; 233(2): 155 - 162. [Abstract] [Full Text] [PDF]

				B. P. Woodall, A. Nystrom, R. A. Iozzo, J. A. Eble, S. Niland, T. Krieg, B. Eckes, A. Pozzi, and R. V. Iozzo Integrin {alpha}2 1 Is the Required Receptor for Endorepellin Angiostatic Activity J. Biol. Chem., January 25, 2008; 283(4): 2335 - 2343. [Abstract] [Full Text] [PDF]

				G. Brideau, M. J. Makinen, H. Elamaa, H. Tu, G. Nilsson, K. Alitalo, T. Pihlajaniemi, and R. Heljasvaara Endostatin Overexpression Inhibits Lymphangiogenesis and Lymph Node Metastasis in Mice Cancer Res., December 15, 2007; 67(24): 11528 - 11535. [Abstract] [Full Text] [PDF]

				J. J. Partridge, M. A. Madsen, V. C. Ardi, T. Papagiannakopoulos, T. A. Kupriyanova, J. P. Quigley, and E. I. Deryugina Functional Analysis of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases Differentially Expressed by Variants of Human HT-1080 Fibrosarcoma Exhibiting High and Low Levels of Intravasation and Metastasis J. Biol. Chem., December 7, 2007; 282(49): 35964 - 35977. [Abstract] [Full Text] [PDF]

				F. B. Furnari, T. Fenton, R. M. Bachoo, A. Mukasa, J. M. Stommel, A. Stegh, W. C. Hahn, K. L. Ligon, D. N. Louis, C. Brennan, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment Genes & Dev., November 1, 2007; 21(21): 2683 - 2710. [Abstract] [Full Text] [PDF]

				F. Bock, J. Onderka, T. Dietrich, B. Bachmann, F. E. Kruse, M. Paschke, G. Zahn, and C. Cursiefen Bevacizumab as a Potent Inhibitor of Inflammatory Corneal Angiogenesis and Lymphangiogenesis Invest. Ophthalmol. Vis. Sci., June 1, 2007; 48(6): 2545 - 2552. [Abstract] [Full Text] [PDF]

				J. S. Isenberg, Y. Jia, J. Fukuyama, C. H. Switzer, D. A. Wink, and D. D. Roberts Thrombospondin-1 Inhibits Nitric Oxide Signaling via CD36 by Inhibiting Myristic Acid Uptake J. Biol. Chem., May 25, 2007; 282(21): 15404 - 15415. [Abstract] [Full Text] [PDF]

				A. Cretu, J. M. Roth, M. Caunt, A. Akalu, D. Policarpio, S. Formenti, P. Gagne, L. Liebes, and P. C. Brooks Disruption of Endothelial Cell Interactions with the Novel HU177 Cryptic Collagen Epitope Inhibits Angiogenesis Clin. Cancer Res., May 15, 2007; 13(10): 3068 - 3078. [Abstract] [Full Text] [PDF]

				J. W. Xuan, M. Bygrave, H. Jiang, F. Valiyeva, J. Dunmore-Buyze, D. W. Holdsworth, J. I. Izawa, G. Bauman, M. Moussa, S. F. Winter, et al. Functional Neoangiogenesis Imaging of Genetically Engineered Mouse Prostate Cancer Using Three-Dimensional Power Doppler Ultrasound Cancer Res., March 15, 2007; 67(6): 2830 - 2839. [Abstract] [Full Text] [PDF]

				L. Ramont, S. Brassart-Pasco, J. Thevenard, A. Deshorgue, L. Venteo, J. Y. Laronze, M. Pluot, J.-C. Monboisse, and F.-X. Maquart The NC1 domain of type XIX collagen inhibits in vivo melanoma growth Mol. Cancer Ther., February 1, 2007; 6(2): 506 - 514. [Abstract] [Full Text] [PDF]

				G. Bix, R. Castello, M. Burrows, J. J. Zoeller, M. Weech, R. A. Iozzo, C. Cardi, M. L. Thakur, C. A. Barker, K. Camphausen, et al. Endorepellin In Vivo: Targeting the Tumor Vasculature and Retarding Cancer Growth and Metabolism. J Natl Cancer Inst, November 15, 2006; 98(22): 1634 - 1646. [Abstract] [Full Text] [PDF]

				Q. Tan, R. Steiner, S. P. Hoerstrup, and W. Weder Tissue-engineered trachea: History, problems and the future Eur. J. Cardiothorac. Surg., November 1, 2006; 30(5): 782 - 786. [Abstract] [Full Text] [PDF]

				S. Maubant, D. Saint-Dizier, M. Boutillon, F. Perron-Sierra, P. J. Casara, J. A. Hickman, G. C. Tucker, and E. Van Obberghen-Schilling Blockade of {alpha}vbeta3 and {alpha}vbeta5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells Blood, November 1, 2006; 108(9): 3035 - 3044. [Abstract] [Full Text] [PDF]

				W. Cai, Y. Wu, K. Chen, Q. Cao, D. A. Tice, and X. Chen In vitro and In vivo Characterization of 64Cu-Labeled AbegrinTM, a Humanized Monoclonal Antibody against Integrin {alpha}v{beta}3 Cancer Res., October 1, 2006; 66(19): 9673 - 9681. [Abstract] [Full Text] [PDF]

				J. Folkman Tumor Suppression by p53 Is Mediated in Part by the Antiangiogenic Activity of Endostatin and Tumstatin Sci. Signal., September 26, 2006; 2006(354): pe35 - pe35. [Abstract] [Full Text] [PDF]

				S. Pal, J. Wu, J. K. Murray, S. H. Gellman, M. A. Wozniak, P. J. Keely, M. E. Boyer, T. M. Gomez, S. M. Hasso, J. F. Fallon, et al. An antiangiogenic neurokinin-B/thromboxane A2 regulatory axis J. Cell Biol., September 25, 2006; 174(7): 1047 - 1058. [Abstract] [Full Text] [PDF]

				D. Sun and K. R. McCrae Endothelial-cell apoptosis induced by cleaved high-molecular-weight kininogen (HKa) is matrix dependent and requires the generation of reactive oxygen species Blood, June 15, 2006; 107(12): 4714 - 4720. [Abstract] [Full Text] [PDF]

				L. Holmgren, E. Ambrosino, O. Birot, C. Tullus, N. Veitonmaki, T. Levchenko, L.-M. Carlson, P. Musiani, M. Iezzi, C. Curcio, et al. A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth PNAS, June 13, 2006; 103(24): 9208 - 9213. [Abstract] [Full Text] [PDF]

				T. E. Battle, R. A. Lynch, and D. A. Frank Signal transducer and activator of transcription 1 activation in endothelial cells is a negative regulator of angiogenesis. Cancer Res., April 1, 2006; 66(7): 3649 - 3657. [Abstract] [Full Text] [PDF]

				V. W.M. van Hinsbergh, M. A. Engelse, and P. H.A. Quax Pericellular Proteases in Angiogenesis and Vasculogenesis Arterioscler. Thromb. Vasc. Biol., April 1, 2006; 26(4): 716 - 728. [Abstract] [Full Text] [PDF]

				D. Faraone, M. S. Aguzzi, G. Ragone, K. Russo, M. C. Capogrossi, and A. Facchiano Heterodimerization of FGF-receptor 1 and PDGF-receptor-{alpha}: a novel mechanism underlying the inhibitory effect of PDGF-BB on FGF-2 in human cells Blood, March 1, 2006; 107(5): 1896 - 1902. [Abstract] [Full Text] [PDF]

				E. I. Deryugina, A. Zijlstra, J. J. Partridge, T. A. Kupriyanova, M. A. Madsen, T. Papagiannakopoulos, and J. P. Quigley Unexpected Effect of Matrix Metalloproteinase Down-Regulation on Vascular Intravasation and Metastasis of Human Fibrosarcoma Cells Selected In vivo for High Rates of Dissemination Cancer Res., December 1, 2005; 65(23): 10959 - 10969. [Abstract] [Full Text] [PDF]

				M. P. Colombo and A. Mantovani Targeting Myelomonocytic Cells to Revert Inflammation-Dependent Cancer Promotion Cancer Res., October 15, 2005; 65(20): 9113 - 9116. [Abstract] [Full Text] [PDF]

				J. FOLKMAN and S. RYEOM Is Oncogene Addiction Angiogenesis-dependent? Cold Spring Harb Symp Quant Biol, January 1, 2005; 70(0): 389 - 397. [Abstract] [PDF]

				M.A. GRANT and R. KALLUR Structural Basis for the Functions of Endogenous Angiogenesis Inhibitors Cold Spring Harb Symp Quant Biol, January 1, 2005; 70(0): 399 - 417. [Abstract] [PDF]